Therapeutic AIDS vaccine designed by the HIVACAT reduces the viral load in the majority of AIDS patients



42 segundos de lectura
Available resources

Although the decrease is not sufficient, the first therapeutic vaccine, designed from the dendritic cells of the actual patient by the Hospital Clinic of Barcelona-IDIBAPS has achieved a significant response in the majority of patients.   The objective of these types of vaccines is to facilitate the treatment of the patients and minimize the antiretroviral drugs that because of their expensive and a life long administration bring about a great economic burden.   L'HIVACAT investigates the development of vaccines against HIV and forms part of the Institut de Recerca de la Sida IrsiCaixa and the Institute of Infectious Diseases and AIDS in Hospital Clinic of Barcelona, in co-ordination with Esteve, the ”La Caixa” foundation, the departments of Health and Economics and Knowledge from the Generalitat de Catalunya and the Fundació Clinic.   More information in the PDF press release